Adagio Therapeutics claims that that its ADG-2 antibody candidate offered strong potency against SARS-CoV-2, as well as a range of pre-emergent coronaviruses.
In in vitro and in vivo test results published January 25, ADG2 was found to bind to all known variants of SARS-CoV-2 and a range of sarbecoviruses that pose a threat to humans.
Additionally, ADG2 yielded protective efficacy in mouse models of SARS and COVID-19 and offered similar or higher potency against SARS-CoV-2 compared with other monoclonal antibodies in development or approved for emergency use.
ADG2, which was able to completely protect mice against severe SARS-CoV-2 and SARS-CoV when they were treated prophylactically. It was able to bind to more than 30 of the most frequently observed SARS-CoV-2 variants, including those resistant to other mAbs in development or approved for emergency use, and more than a dozen sarbecoviruses receptor binding domains.
Adagio said that ADG20 -- its half-life engineered version of ADG2 -- could offer protection against COVID-19 for up to a year. ADG20 is expected to enter phase I clinical studies in early 2021.
In in vitro and in vivo test results published January 25, ADG2 was found to bind to all known variants of SARS-CoV-2 and a range of sarbecoviruses that pose a threat to humans.
Additionally, ADG2 yielded protective efficacy in mouse models of SARS and COVID-19 and offered similar or higher potency against SARS-CoV-2 compared with other monoclonal antibodies in development or approved for emergency use.
ADG2, which was able to completely protect mice against severe SARS-CoV-2 and SARS-CoV when they were treated prophylactically. It was able to bind to more than 30 of the most frequently observed SARS-CoV-2 variants, including those resistant to other mAbs in development or approved for emergency use, and more than a dozen sarbecoviruses receptor binding domains.
Adagio said that ADG20 -- its half-life engineered version of ADG2 -- could offer protection against COVID-19 for up to a year. ADG20 is expected to enter phase I clinical studies in early 2021.
